The patient – born in 1960, was first diagnosed in 1981 as having malignant carcinoid of the right lung.
The disease relapsed in 2002 in a form of distant dissemination. According to tumor histology – atypical
carcinoid – this patient was initially treated with palliative systemic chemotherapy, specifically with
cisplatin and etoposid. His disease stabilized after administration of 4 cycles of chemotherapy. The
treatment was accompanied by protracted toxicity with marked alteration of his general conditions after
the 4th cycle. Upon request of his relatives, the patient was referred to Masaryk Memorial Cancer
Institute to receive supportive care. His general conditions then stabilized but intermittent episodic
abdominal discomfort with occasional vomiting persisted. Due to positive octreoscan, the patient was
given somatostatin analogues with a very good and long-term clinical effect. The symptoms disappeared,
except a persisting ocular disorder due to periorbital infiltration. The patient state improved allowing
further outpatient care. When somatostatin analogues were discontinued, serum chromogranin A rose
rapidly and was accompanied by new appearance of symptoms. After re-administering somatostatin
analogues the symptoms disappeared and the concentration of serum chromogranin A decreased. The
patient has been still (with two 5,5 years interruptions) treated with somatostatin analogues with very
good tolerance and clinical effect – at present there are no symptoms of the disease and, according to
imaging methods, long-term stabilization continues. This case study illustrates the necessity of cautious
and individual approach to the choice of treatment strategy in patients with malignant carcinoid.
carcinoid, somatostatin analogues, chromogranin, octreotid, lanreotid.